Your AI-Trained Oncology Knowledge Connection!
Benjamin P. Levy, MD, is clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at Johns Hopkins University School of Medicine.
Panelists discuss how the DeLLphi-301 trial demonstrated that tarlatamab, administered biweekly at a 10 mg dose, achieved a 40% objective response rate in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). This led to its accelerated FDA approval in May 2024. Integrating tarlatamab into clinical practice may present challenges, including managing cytokine release syndrome and neurologic toxicities, as well as addressing financial considerations.
Panelists discuss how recent real-world data comparing atezolizumab and durvalumab in extensive-stage non–small cell lung cancer (ES-NSCLC) informs treatment selection, though direct comparisons remain limited. Lurbinectedin is a key second-line option, with emerging combination strategies.
Panelists discuss how the ADRIATIC regimen integrates immunotherapy post-chemoradiation in late-stage small cell lung cancer (LS-SCLC). In patients with paraneoplastic syndromes or immune disorders, immunotherapy requires caution. Prophylactic cranial irradiation (PCI) is considered for high-risk cases, while MRI surveillance is preferred for select patients to reduce neurotoxicity.
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.
Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.
The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.
The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.
A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.
Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.
The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.
Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.
A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.
Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).
Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.
Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
